SCYX

SCYNEXIS to Present at the BIO Digital International Convention 2021

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

Scynexis Raises $60M Via Term Loan Ahead Of Expected Approval Of Vaginal Yeast Infection Treatment

SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank

SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch